Search
BCc1
go.drugbank.com/drugs/DB16504ExperimentalBCc1 is a nanomedicine that demonstrated potent anticancer effects in both in vitro and in vivo studies.
SOR-C13
go.drugbank.com/drugs/DB15366InvestigationalSOR-C13 is under investigation in clinical trial NCT01578564 (Safety and Tolerability Study of SOR-C13 in Subjects With Advanced Cancers Commonly Known to Express the TRPV6 Channel).
Categories: Ion ChannelsM0002
go.drugbank.com/drugs/DB05091InvestigationalM0002 is an orally-active selective vasopressin antagonist that inhibits water re-absorption from the kidneys. … It is a vasopressin 2 antagonist and represents a new class of compounds – aquaretics – that produce profound diuresis without loss of electrolytes.
PN0621
go.drugbank.com/drugs/DB05218ExperimentalIt is being developed by Peptech. … PN0621 is an anti-TNF, domain antibody (dAb) based therapeutic. It targets tumour necrosis factor (TNF) to treat auto-immune inflammatory diseases such as rheumatoid arthritis.
Gosogliptin
go.drugbank.com/drugs/DB08382InvestigationalGosogliptin has been used in trials studying the treatment of Renal Insufficiency, Chronic.
Categories: DPP-IV InhibitorsVGV-1
go.drugbank.com/drugs/DB05328ExperimentalVGV-1 is a potential salvage therapy for treatment of HIV infected people who have failed anti-retroviral therapy.
Neramexane
go.drugbank.com/drugs/DB04926InvestigationalNeramexane is a low-to-moderate affinity uncompetitive NMDA receptor antagonist.
Quinacrine
go.drugbank.com/drugs/DB01103InvestigationalIt has also been used as an anthelmintic and in the treatment of giardiasis and malignant effusions. It is used in cell biological experiments as an inhibitor of phospholipase A2. … An acridine derivative formerly widely used as an antimalarial but superseded by chloroquine in recent years.